Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171


Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.

Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA, Witztum JL.

Circulation. 2009 Apr 7;119(13):1711-9. doi: 10.1161/CIRCULATIONAHA.108.836940. Epub 2009 Mar 23.


LPA Gene, Ethnicity, and Cardiovascular Events.

Lee SR, Prasad A, Choi YS, Xing C, Clopton P, Witztum JL, Tsimikas S.

Circulation. 2017 Jan 17;135(3):251-263. doi: 10.1161/CIRCULATIONAHA.116.024611. Epub 2016 Nov 9.


The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.

Arai K, Luke MM, Koschinsky ML, Miller ER, Pullinger CR, Witztum JL, Kane JP, Tsimikas S.

Atherosclerosis. 2010 Apr;209(2):498-503. doi: 10.1016/j.atherosclerosis.2009.09.077. Epub 2009 Oct 12.


Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.

Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S.

Circulation. 2008 Aug 12;118(7):743-53. doi: 10.1161/CIRCULATIONAHA.108.786822. Epub 2008 Jul 28.


Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.

Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL.

J Am Coll Cardiol. 2006 Jun 6;47(11):2219-28. Epub 2006 May 15.


Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1788-95. Epub 2007 May 31.


Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study.

Kamstrup PR, Hung MY, Witztum JL, Tsimikas S, Nordestgaard BG.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1570-1578. doi: 10.1161/ATVBAHA.116.308761. Epub 2017 Jun 1.


Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.

Rao F, Schork AJ, Maihofer AX, Nievergelt CM, Marcovina SM, Miller ER, Witztum JL, O'Connor DT, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1704-11. doi: 10.1161/ATVBAHA.115.305306. Epub 2015 May 7.


High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men.

Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L.

Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2619-24.


Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Enkhmaa B, Anuurad E, Zhang W, Berglund L.

Atherosclerosis. 2014 Jul;235(1):223-9. doi: 10.1016/j.atherosclerosis.2014.04.035. Epub 2014 May 10.


Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).

Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, Brilakis E, Kornman KS, Witztum JL.

J Am Coll Cardiol. 2014 May 6;63(17):1724-34. doi: 10.1016/j.jacc.2013.12.030. Epub 2014 Feb 12.


Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).

Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, Tsimikas S.

J Clin Lipidol. 2016 May-Jun;10(3):594-603. doi: 10.1016/j.jacl.2016.01.005. Epub 2016 Mar 8.


Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.

Paultre F, Tuck CH, Boden-Albala B, Kargman DE, Todd E, Jones J, Paik MC, Sacco RL, Berglund L.

Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):141-6.


High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.

Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Sep 14;110(11):1406-12. Epub 2004 Sep 7.


Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.

Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H.

J Lipid Res. 1996 Dec;37(12):2569-85.


Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators.

J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.


Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Taleb A, Witztum JL, Tsimikas S.

Biomark Med. 2011 Oct;5(5):673-94. doi: 10.2217/bmm.11.60. Review.


Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.

Prasad A, Clopton P, Ayers C, Khera A, de Lemos JA, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1213-1221. doi: 10.1161/ATVBAHA.117.309101. Epub 2017 May 4.


Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study.

Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH.

Circulation. 2005 Mar 29;111(12):1471-9. Epub 2005 Mar 21.

Supplemental Content

Support Center